Long-term Follow-up of Subjects Treated With CAR T Cells
Launched by MARCELA V. MAUS, M.D.,PH.D. · Aug 23, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the long-term effects of a treatment called CAR T cells, which is used for certain types of cancer. The goal is to check how safe this treatment is over a longer period and to see how well it continues to work for people after their initial treatment. The study is currently looking for participants who have already received CAR T cell therapy in earlier studies and are willing to provide their consent to take part in this follow-up.
To be eligible for the trial, participants should be aged 65 years or older and must have previously received CAR T cell treatment as part of the main study. If you join the study, you can expect to be monitored for any long-term side effects and to share your health updates with the research team. It's important to note that you would need to be able to follow the study's requirements to participate. This trial aims to gather valuable information that could help improve future cancer treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects will be asked to participate leading up to the last DF/HCC corresponding main study visit.
- Subjects meeting the following criteria are eligible for study participation:
- • Provision of voluntary written informed consent by subject
- • CAR T cells were administered in DF/HCC IRB corresponding main study
- Exclusion Criteria:
- Subjects meeting the following criterion are to be excluded from study participation:
- • - Subject unable to comply with study requirements
About Marcela V. Maus, M.D.,Ph.D.
Dr. Marcela V. Maus, M.D., Ph.D., is a distinguished clinical trial sponsor renowned for her expertise in the field of oncology and immunotherapy. With a robust background in both medicine and research, Dr. Maus has made significant contributions to the development of innovative therapeutic strategies aimed at harnessing the immune system to combat cancer. Her leadership in clinical trials is characterized by a commitment to advancing patient care through rigorous scientific inquiry, collaboration, and a focus on translating laboratory discoveries into effective clinical applications. Dr. Maus's work is pivotal in shaping the future of cancer treatment, making her a key figure in the ongoing pursuit of breakthroughs in this critical area of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Matthew J Frigault, MD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials